Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat

Journal of Medicinal Chemistry

Volumn 42, Issue 16, 1999, Pages 3175-3182

  Rivier, Jean E ^a   Kirby, Dean A ^a   Lahrichi, Sabine L ^a   Corrigan, Anne ^a   Vale, Wylie W ^a   Rivier, Catherine L ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTRESSIN B; ASTRESSIN DERIVATIVE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DOSE TIME EFFECT RELATION; DRUG CONFORMATION; DRUG DEGRADATION; DRUG ELIMINATION; HORMONAL REGULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENALECTOMY; AMINO ACID SEQUENCE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORTICOTROPIN-RELEASING HORMONE; ELECTROPHORESIS, CAPILLARY; HUMANS; MALE; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PITUITARY GLAND, ANTERIOR; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033549886     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902133     Document Type: Article

References (67)

1. Rivier, J.; Gulyas, J.; Corrigan, A.; Craig, A. G.; Martinez, V.; Taché, Y.; Vale, W.; Rivier, C. Astressin analogues (CRF antagonists) with extended duration of action in the rat. J. Med. Chem. 1998, 41, 5012-5019.
2. Hernandez, J.-F.; Kornreich, W.; Rivier, C.; Miranda, A.; Yamamoto, G.; Andrews, J.; Taché, Y.; Vale, W. W.; Rivier, J. E. Synthesis and relative potencies of new constrained CRF antagonists. J. Med. Chem. 1993, 36, 2860-2867.
3. Guillemin, R.; Rosenberg, B. Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures. Endocrinology 1955, 57, 599-607.
4. Saffran, M.; Schally, A. V. The release of corticotrophin by anterior pituitary tissue in vitro. Can. J. Biochem. Physiol. 1955, 33, 408-415.
5. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 1981, 213, 1394-1397.
6. Rivier, J.; Spiess, J.; Vale, W. Characterization of rat hypothalamic corticotropin-releasing factor. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 4851-4855.
7. Shibahara, S.; Morimoto, Y.; Furutani, Y.; Notake, M.; Takahashi, H.; Shimizu, S.; Horikawa, S.; Numa, S. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. Embo. J. 1983, 2 (5), 775-779.
8. Rivier, C.; Plotsky, P. M. Mediation by corticotropin-releasing factor (CRF) of adenohypophysial hormone secretion. In Annual Review of Physiology; Berne, R. M., Ed.; Academic Press: Palo Alto, CA, 1986; Vol. 48, pp 475-494.
9. Irwin, M. R.; Vale, W.; Britton, K. T. Central corticotropin-releasing factor suppresses natural killer cytotoxicity. Brain Behav. Immun. 1987, 1, 81-87.
10. Rivest, S.; Rivier, C. The role of corticotropin-releasing factor and interleukin-1 in the regulation of neurons controlling reproductive functions. Endocr. Rev. 1995, 16, 177-199.
11. Brown, M.; Fisher, L. Regulation of the autonomic nervous system by corticotropin-releasing factor. In Corticotropin-releasing factor: Basic and clinical studies of a neuropeptide; DeSouza, E., Nemeroff, C. B., Eds.; CRC Press: Boca Raton, FL, 1990; pp 292-298.
12. Fisher, L. A. Central actions of corticotropin-releasing factor on autonomic nervous activity and cardiovascular functioning. In Proceedings of the Ciba Foundation Symposium No. 172 on Corticotropin-Releasing Factor; Chadwick, D. J., Marsh, J., Ackrill, K., Eds.; John Wiley & Sons: New York, 1993; pp 243-257.
13. Brown, M. R. Brain peptide regulation of autonomic nervous and neuroendocrine functions. In Stress Neurobiology and Neuroendocrinology; Brown, M. R., Koob, G. F., Rivier, C., Eds.; Marcel Dekker: New York, 1991; pp 193-215.
14. Heinrichs, S. C.; Menzaghi, F.; Schulteis, G.; Koob, G. F.; Stinus, L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav. Pharmacol. 1995, 6, 74-80.
15. Menzaghi, F.; Rassnick, S.; Heinrichs, S.; Baldwin, H.; Pich, E.; Weiss, F.; Koob, G. The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann. NY Acad. Sci. 1994, 739, 176-184.
16. Koob, G. F.; Heinrichs, S. C.; Pich, E. M.; Menzaghi, F.; Baldwin, H.; Miczek, K.; Britton, K. T. The role of corticotropin-releasing factor in behavioural responses to stress. In Proceedings of the Ciba Foundtaion Symposium No. 172 on Corticotroin-Releasing Factor; Chadwick, D. J., Marsh, J., Ackrill, K., Eds.; John Wiley & Sons: New York, 1993; pp 277-295.
17. Gold, P. W.; Wong, M.-L.; Chrousos, G. P.; Licinio, J. Stress system abnormalities in melancholic and atypical depression: molecular, pathophysiological, and therapeutic implications. Mol. Psychiat. 1996, 1, 257-264.
18. Britton, K. T.; Lee, G.; Vale, W.; Rivier, J.; Koob, G. F. Corticotropin releasing factor (CRF) receptor antagonist blocks activating and 'anxiogenic' actions of CRF in the rat. Brain Res. 1986, 369, 303-306.
19. Koob, G. F. Behavioral responses to stress-focus on corticotropin releasing factor. In Neurobiology and Neuroendocrinology of Stress; Brown, M. R., Rivier, C., Koob, G., Eds.; Marcel Dekker: New York, 1990; pp 255-274.
20. Munck, A.; Guyre, P. M. Glucocorticoid physiology, pharmacology and stress. Adv. Exp. Med. Biol. 1986, 196, 81-96.
21. Dallman, M. F.; Strack, A. M.; Akana, S. F.; Bradbury, M. J.; Hanson, E. S.; Scribner, K. A.; Smith, M. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front. Neuroendocrinol. 1993, 14, 303-347.
22. Chen, R.; Lewis, K. A.; Perrin, M. H.; Vale, W. W. Expression cloning of a human corticotropin releasing factor (CRF) receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8967-8971.
23. Chang, C. P.; Pearse, R. V., II; O'Connell, S.; Rosenfeld, M. G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993, 11, 1187-1195.
24. Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilezikjian, L.; Sawchenko, P.; Vale, W. Identification of a second CRF receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2969-2973.
25. Kishimoto, T.; Pearse, R. V., II; Lin, C. R.; Rosenfeld, M. G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1108-1112.
26. Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Lelias, J. M.; Kaghad, M.; Le, F. G.; Caput, D.; Ferrara, P. Primary structure and functional expression of mouse pituitary and human brain corticotropin releasing factor receptors. FEBS Lett. 1993, 335, 1-5.
27. Lovenberg, T. W.; Liaw, C. W.; Grigoriadis, D. E.; Clevenger, W.; Chalmers, D. T.; DeSouza, E. B.; Oltersdorf, T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 836-840.
28. Perrin, M. H.; Donaldson, C. J.; Chen, R.; Lewis, K. A.; Vale, W. W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 1993, 133, 3058-3061.
29. Martinez, V.; Rivier, J.; Wang, L.; Taché, Y. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J. Pharmacol. Exp. Ther. 1997, 280, 754-760.
30. 1 receptor antagonists. J. Med. Chem. 1996, 39, 4358-4360.
31. Wustrow, D. J.; Capiris, T.; Rubin, R.; Knobelsdorf, J. A.; Akunne, H.; Davis, M. D.; MacKenzie, R.; Pugsley, T. A.; Zoski, K. T.; Heffner, T. G.; Wise, L. D. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 2067-2070.
32. Hodge, C. N.; Aldrich, P. E.; Wasserman, Z. R.; Fernandez, C. H.; Nemeth, G. A.; Arvanitis, A.; Cheeseman, R. S.; Chorvat, R. J.; Ciganek, E.; Christos, T. E.; Gilligan, P. J.; Krenitsky, P.; Scholfield, E.; Strucely, P. Corticotropin-releasing hormone receptor antagonists: Framework design and synthesis guided by ligand conformational studies. J. Med. Chem. 1999, 42, 819-832.
33. Arvanitis, A. G.; Gilligan, P. J.; Chorvat, R. J.; Cheeseman, R. S.; Christos, T. E.; Bakthavatchalam, R.; Beck, J. P.; Cocuzza, A. J.; Hobbs, F. W.; Wilde, R. G.; Arnold, C.; Chidester, D.; Curry, M.; He, L.; Hollis, A.; Klaczkiewicz, J.; Krenitsky, P. J.; Rescinito, J. P.; Scholfield, E.; Culp, S.; De Souza, E. B.; Fitzgerald, L.; Grigoriadis, D.; Tam, S. W.; Wong, Y. N.; Huang, S.-M.; Shen, H. L. Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J. Med. Chem. 1999, 42, 805-818.
34. Chorvat, R. J.; Bakthavatchalam, R.; Beck, J. P.; Gilligan, P. J.; Wilde, R. G.; Cocuzza, A. J.; Hobbs, F. W.; Cheeseman, R. S.; Curry, M.; Rescinito, J. P.; Krenitsky, P.; Chidester, D.; Yarem, J. A.; Klaczkiewicz, J. D.; Hodge, C. N.; Aldrich, P. E.; Wasserman, Z. R.; Fernandez, C. H.; Zaczek, R.; Fitzgerald, L. W.; Huang, S.-M.; Shen, H. L.; Wong, Y. N.; Chien, B. M.; Quon, C. Y.; Arvanitis, A. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. J. Med. Chem. 1999, 42, 833-848.
35. 1 receptor antagonists. J. Med. Chem. 1996, 39, 4354-4357.
36. 1 receptor antagonist. J. Med. Chem. 1997, 40, 1749-1754.
37. Schulz, D. W.; Mansbach, R. S.; Sprouse, J.; Braselton, J. P.; Collins, J.; Corman, M.; Dunaiskis, A.; Faraci, S.; Schmidt, A. W.; Seeger, T.; Seymour, P.; Tingley, F. D., III; Winston, E. N.; Chen, Y. L.; Heym, J. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10477-10482.
38. Barquist, E.; Zinner, M.; Rivier, J.; Taché, Y. Abdominal surgery-induced delayed gastric emptying in rats: role of CRF and sensory neurons. Am. J. Physiol. 1992, 262, G616-G620.
39. Raybould, H. E.; Koelbel, C. B.; Mayer, E. A.; Taché, Y. Inhibition of gastric motor function by circulating corticotropin-releasing factor in anesthetized rats. J. Gastrointest. Motil. 1990, 2, 265-272.
40. Williams, C. L.; Peterson, J. M.; Villar, R. G.; Burks, T. F. Corticotropin-releasing factor directly mediates colonic responses to stress. Am. J. Physiol. 1987, 253, G582-G586.
41. Taché, Y.; Maeda-Hagiwar, M.; Turkelson, C. M. Central nervous system action of corticotorpin-releasing factor to inhibit gastric empyting in rats. Am. J. Physiol. 1987, 253, G241-G245.
42. Sheldon, R. J.; Qui, J. A.; Porreca, F.; Fisher, L. A. Gastrointestinal motor effects of corticotropin-releasing factor in mice. Regul. Pept. 1990, 28, 137-151.
43. Pappas, T.; Debas, H.; Taché, Y. Corticotropin-releasing factor inhibits gastric emptying in dogs. Regul. Pept. 1985, 11, 193-199.
44. Lenz, H. J.; Burlage, M.; Raekdler, A.; Greten, H. Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. Gastroenterology 1988, 94, 598-602.
45. Broccardo, M.; Improta, G. Pituitary-adrenal and vagus modulation of sauvagine- and CRF-induced inhibition of gastric emptying in rats. Eur. J. Pharmacol. 1990, 182, 357-362.
46. Nozu, T.; Martínez, V.; Rivier, J.; Taché, Y. Peripheral urocortin delays gastric emptying: role of CRF 2 receptors. Am. J. Physiol.: Gastrointest. Liver Physiol. 1999, 39, G867-G874.
47. Martínez, V.; Rivier, J.; Taché, Y. The new corticotropinreleasing factor (CRF) antagonist, Astressin is a potent inhibitor of peripheral CRF and abdominal surgery-induced delayed emptying in rats. J. Pharmacol. Exp. Ther. 1999, in press.
48. Baram, T. Z.; Mitchell, W. G.; Haden, E. Inhibition of pituitary-adrenal secretion by a corticotropin releasing hormone antagonist in humans. Mol. Psychiat. 1996, 1, 320-324.
49. Chrousos, G. P.; Gold, P. W. Editorial: A healthy body in a healthy mind - and vice versa - the damaging power of "uncontrollable" stress. J. Clin. Endocrinol. Metab. 1998, 83, 1842-1845.
50. Dudley, D. J. Immunoendocrinology of preterm labor: The link between corticotropin-releasing hormone and inflammation. Am. J. Obstet. Gynecol. 1999, 180, S251-S256.
51. Felix, A. M.; Heimer, E. P.; Wang, C. T.; Lambros, T. J.; Fournier, A.; Mowles, T. F.; Maines, S.; Campbell, R. M.; Wegrzynski, B. B.; Toome, V.; Fry, D.; Madison, V. S. Synthesis, biological activity and conformational analysis of cyclic GRF analogues. Int. J. Pept. Prot. Res. 1988, 32, 441-454.
52. Miranda, A.; Koerber, S. C.; Gulyas, J.; Lahrichi, S.; Craig, A. G.; Corrigan, A.; Hagler, A.; Rivier, C.; Vale, W.; Rivier, J. Conformationally restricted competitive antagonists of human/ rat corticotropin-releasing factor. J. Med. Chem. 1994, 37, 1450-1459.
53. Miranda, A.; Lahrichi, S. L.; Gulyas, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W. W.; Rivier, J. E. Constrained corticotropin releasing factor (CRF) antagonists with i-(i+3) Glu - Lys bridges. J. Med. Chem. 1997, 40, 3651-3658.
54. Rivier, J.; Lahrichi, S. L.; Gulyas, J.; Erchegyi, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W. Minimal-size, constrained corticotropin releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges. J. Med. Chem. 1998, 41, 2614-2620.
55. Hudson, D. J. Methodological implications of simultaneous solid-phase peptide synthesis. 1. Comparison of different coupling procedures. J. Org. Chem. 1988, 53, 617-624.
56. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
57. Hoeger, C.; Galyean, R.; Boublik, J.; McClintock, R.; Rivier, J. Preparative reversed phase high performance liquid chromatography. II. Effects of buffer pH on the purification of synthetic peptides. Biochromatography 1987, 2, 134-142.
58. Rivier, J. Use of trialkylammonium phosphate (TAAP) buffers in reverse phase HPLC for high resolution and high recovery of peptides and proteins. J. Liq. Chromatogr. 1978, 1, 343-367.
59. Koerber, S. C.; Gulyas, J.; Lahrichi, S. L.; Corrigan, A.; Craig, A. G.; Rivier, C.; Vale, W. W.; Rivier, J. Constrained corticotropin releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges. J. Med. Chem. 1998, 41, 5002-5011.
60. Rivier, J.; Rivier, C.; Vale, W. Synthetic competitive antagonists of corticotropin releasing factor: Effect on ACTH secretion in the rat. Science 1984, 224, 889-891.
61. Vale, W.; Vaughan, J.; Yamamoto, G.; Bruhn, T.; Douglas, C.; Dalton, D.; Rivier, C.; Rivier, J. Assay of corticotropin releasing factor. In Methods in Enzymology: Neuroendocrine Peptides; Conn, P. M., Eds.; Academic Press: New York, 1983; Vol. 103, pp 565-577.
62. Beyermann, M.; Fechner, K.; Furkert, J.; Krause, E.; Bienert, M. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J. Med. Chem. 1996, 39, 3324-3330.
63. Rivier, J.; Rivier, C.; Galyean, R.; Miranda, A.; Miller, C.; Craig, A. G.; Yamamoto, G.; Brown, M.; Vale, W. Single point D-substituted corticotropin releasing factor analogues: Effects on potency and physicochemical characteristics. J. Med. Chem. 1993, 36, 2851-2859.
64. Hernandez, J.-F.; Kornreich, W.; Rivier, C.; Miranda, A.; Yamamoto, G.; Andrews, J.; Taché, Y.; Vale, W.; Rivier, J. Synthesis and relative potencies of new constrained CRF antagonists. J. Med. Chem. 1993, 36, 2860-2867.
65. Felix, A. M.; Wang, C.-T.; Heimer, E. P.; Fournier, A. Applications of BOP reagent in solid-phase synthesis. II. Solid-phase side-chain to side-chain cyclizations using BOP reagent. Int. J. Pept. Prot. Res. 1988, 31, 231-238.
66. Miller, C.; Rivier, J. Analysis of synthetic peptides by capillary zone electrophoresis in organic/aqueous buffers. J. Pept. Res. 1998, 51, 444-451.
67. Rivier, C.; Shen, G. H. In the rat, endogenous nitric oxide modulates the response of the hypothalamic-pituitary-adrenal axis to interleukin-1β, vasopressin and oxytocin. J. Neurosci. 1994, 14, 1985-1993.